Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Sildenafil (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Acronyms SIL02
- 28 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 28 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 May 2020.
- 24 Sep 2018 According to a Food and Drug Administration media release, USFDA awarded the trial with research grant.